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Abstract
Preterm birth remains a major cause of perinatal mortality and long term handicap in surviving
infants. This is one of the most important clinical problems in Europe and across the world. While
some preterm births are iatrogenic, associated with severe complications of pregnancy (e.g.
hypertensive disorders, antepartum haemorrhage, infection), or the result of multiple pregnancies
following assisted reproduction, a high proportion of preterm births occur following spontaneous
preterm labour of unknown cause. Early intervention in this group of women would have a
significant impact on neonatal mortality and morbidity figures. However, the endocrine changes
preceding parturition in women remain elusive and this makes it difficult to predict spontaneous
labour at term, let alone preterm labour. Moreover our understanding of myometrial physiology
remains rudimentary, limiting our options to devise improved pharmacological strategies to control
uterine contractility when this is indicated. There is a need for concerted European and
international research efforts to improve our knowledge of the mechanism of labour in women, to
identify diagnostic markers to predict preterm labour and to develop uterine selective drugs to
inhibit uterine contractions in a safe and efficient manner. This aim will be achieved by
multidisciplinary research efforts from academics and industry, using traditional laboratory and
clinical research methods, as well as novel technologies.
The problem of preterm labour
The factor(s) controlling the spontaneous onset of labour
are not known. This is frustrating from a physiological
point of view, and it is also a major clinical problem.
Spontaneous preterm deliveries (before 37 completed
weeks of gestation) account for 10% of all births and yet
they account for 75% of neonatal deaths. Thus alterations
in the timing of the onset of labour per se (excluding con-
genital malformations and elective preterm deliveries for
severe complications of pregnancy) are a major contribu-
tor to perinatal mortality [1,2]. The last trimester of preg-
nancy is necessary for the maturation of the fetal lungs
and other organs in preparation for extrauterine life. If this
process is interrupted by an early delivery the chances of
survival of the newborn are severely decreased. The mor-
tality rate is higher at lower gestational ages. For example
it increases from 2 ‰ (two per thousand deliveries) at
37–40 weeks, to 18 ‰ at 32–36 weeks and 216 ‰ at 24–
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31 weeks [3]. Despite considerable improvements in spe-
cial care baby units the perinatal mortality rates in the UK
remain steady, and there is a wide range of both short-
term and long-term morbidity and handicap in the surviv-
ing infants [4,5]. The challenges of extreme prematurity
often make international headlines in the Western media,
but prematurity affects both rich and developing coun-
tries.
The uterus is a myogenic organ and it contracts spontane-
ously following waves of electrical activity that result in
membrane depolarization, a rise in intracellular calcium
and the generation of force. While uterine activity can
occur in the absence of hormonal or neural stimulation,
the activation of a number of G protein coupled receptors
(GPCRs) present on myometrial cells has profound stim-
ulatory or inhibitory effects on contractions. For example,
receptors coupled to Gαq e.g. oxytocin receptors (OXTR),
endothelin-receptors (EDNRA), some prostanoids recep-
tors (PTGER1, PTGFR, TBXA1R), stimulate contractility by
activating the phospholipase C/Ca2+ pathway; receptors
coupled to Gαs e.g.  β2-adrenoceptors (ADRB2), prosta-
noid PTGDR, PTGER2 and PTGIR relax the uterus by stim-
ulating adenylyl cyclase (ADCY) and increasing
myometrial cyclic AMP levels; and receptors coupled to
Gαi e.g. α2-adrenoceptors (ADRA2), muscarinic receptors
(CHRM), potentiate contractility, probably by inhibiting
cyclic AMP production [6]. The uterus responds to many
agonists, hence changes in the level of receptor expression
and coupling to intracellular signalling pathways are
likely to be involved in the regulation of uterine contrac-
tility. Uterine quiescence during pregnancy and the
increased activity associated with the spontaneous onset
of labour are likely to be reflected by changes in myome-
trial receptor function [6,7].
Endocrinology of parturition
For many years the overwhelming candidate responsible
for pregnancy maintenance has been progesterone. This is
based on the fact that in mammals the onset of labour is
associated with mechanisms that result in maternal pro-
gesterone withdrawal. In the sheep parturition is initiated
by activation of the fetal pituitary-adrenal axis [8], with
increased fetal cortisol secretion [9], followed by the acti-
vation of placental cytochrome P450 (CYP17A family)
enzymes with 17α hydroxylase and 17–20 lyase activities
[10]. As a consequence of this glucocorticoids-dependent
enzyme activation there is increased conversion of C19- to
C18-steroids, so that maternal progesterone levels fall and
oestradiol levels rise [8]. These steroid changes promote
increased intrauterine production of prostaglandins, cer-
vical softening and uterine contractions. Moreover, fetal
adrenal cortisol induces prostaglandin synthase type 2 in
placental trophoblast with an increase in prostaglandin
E2 production which reinforces the activation of the P450
cascade [11]. In corpus luteum-dependent species (goats,
rabbits, rats, mice), the onset of labour is triggered by the
release of prostaglandin F2α from the endometrium lead-
ing to the demise of the corpus luteum. Luteolysis is medi-
ated by activation of prostaglandin F receptors (PTGFR)
[12] and provokes a fall in maternal progesterone levels,
which is rapidly followed by the onset of labour.
The factors responsible for parturition in women remain
unknown and the endocrine paradigms described above
do not fit primates. Progesterone production from the cor-
pus luteum is essential in early human pregnancy, but the
organ is not required for the last two thirds of gestation
when progesterone production is taken over by the pla-
centa [13]. Moreover, there is no induction of placental
CYP17A enzymes by cortisol around the time of parturi-
tion and the levels of progesterone and oestrogens remain
stable. Progesterone is metabolised by 20α-hydroxyster-
oid dehydrogenase in uterine tissues [14] but there is no
conclusive evidence that the activity of this enzyme alters
the local oestrogen/progesterone ratio before parturition.
The fetal pituitary-adrenal axis, which is very active in late
gestation, appears to have only a supportive role in
human parturition. Observations in anencephaly preg-
nancies with no residual pituitary/adrenal function
showed that the mean length of gestation was similar to
that in women carrying normal singleton fetuses, but with
a much wider scatter around the mean [15]. This suggests
that normal fetal pituitary adrenal function is required for
the fine-tuning of the timing of parturition but that spon-
taneous labour can still occur in anencephaly. In pri-
mates, the fetal adrenal produces large amounts of
androgen precursors, notably dehydroepiandrosterone
sulphates, which are converted to oestrogens in the pla-
centa by sulphatase and aromatase activities. Remarkably,
normal pregnancy and parturition have been reported in
patients with placental sulphatase or aromatase deficien-
cies with very low levels of oestrogens [16]. Thus, in
women changes in circulating steroid levels are not a pre-
requisite for the onset of labour.
Nevertheless our understanding of steroid action in the
pregnant uterus is incomplete and further research in this
area will be beneficial. It has been proposed that parturi-
tion in women results from coordinated functional pro-
gesterone withdrawal and oestrogen activation in
myometrial tissue [17,18]. The progesterone receptor
(PGR) is a ligand-activated transcription factor of the ster-
oid receptor superfamily. Human progesterone receptors
exist in three isoforms originating from the same gene, a
full length 116 kDa PGR-B and two smaller N-terminally
truncated forms, a 94 kDa PGR-A and a 60 kDa PGR-C
[19,20]. Binding of progesterone to PGR-B results in acti-
vation of progesterone-responsive genes, however in myo-BMC Pregnancy and Childbirth 2007, 7(Suppl 1):S2 http://www.biomedcentral.com/1471-2393/7/S1/S2
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metrial cells the action of PGR-B is antagonised by PGR-A
which acts as a dominant repressor of transcription [21].
Some studies suggest that the relative abundance of PGR-
A over PGR-B in human myometrium increases in labour,
leading to functional progesterone withdrawal [21,22].
This switch is accompanied by an increase in oestrogen
receptor transcripts [22] which potentially could result in
increased oestrogen responsiveness. It is not known what
brings about the changes in PGR expression in the uterus
at the time of parturition; however it is possible that these
are mediated by changes in histone acetylase activity
which is required for PGR transcription. In mice the use of
a histone deacetylase inhibitor delayed significantly the
onset of labour [23]. Recent data suggest that labour is
associated with an increase in PGR-C isoforms, probably
mediated through the NFKB pathway [24]. PGR-C reside
mainly in the cytosol of myometrial cells and it is thought
that the increase in PGR-C/PGR-B ratio takes progesterone
away from PGR-B leading to low PGR binding to nuclear
chromatin in myometrium in labour [24,25]. The concept
that PGR-B, as opposed to PGR-A or PGR-C, is essential to
progesterone action in myometrium appears to be chal-
lenged by experiments in transgenic mice that show that
PGR-A and PGR-B have overlapping, rather than antago-
nistic actions in fertility and uterine function [26]. More-
over the functional role of PGR isoforms may be
dependent on the availability of specific co-regulators
such as the cAMP-response element-binding protein
(CREB)-binding protein [23] the steroid receptor coacti-
vators 2 and 3 and [23,27] and the protein-associated
splicing factor SFPQ [28]. Experiments in pregnant rats
have shown that SFPQ inhibits the transcriptional activity
of PGR by a mechanism that involves blocking nuclear
progesterone response elements and by promoting
increased catabolism of PGR [28]. It will be of interest to
study these mechanisms in human pregnant myometrium
near term.
A new approach to our understanding of progesterone
function has followed the description of membrane-
bound isoforms of the PGR (mPGR) resembling GPCRs in
human myometrium [29,30]. The signalling pathway for
mPGR has been investigated in human myometrial cells
and the evidence suggests that the receptor stimulates
mitogen-activated protein kinases (MAPK) through a Gi
dependent mechanism. Moreover activation of mPGRs
leads to inhibition of cAMP synthesis and phosphoryla-
tion of MYL by MAPK [29]. This poses the challenging
hypothesis that progesterone may participate both in
pregnancy maintenance and in the stimulation of myo-
metrial contractility at the onset of labour through the
interplay of intracellular PGR receptors and Gi-coupled
mPGR proteins. Further research into the functional role
of the different PGR proteins in myometrium will be of
great interest.
Gene regulation
There is very little information on the regulation of genes
that promote uterine relaxation in pregnancy. An impor-
tant concept is that uterine relaxation in pregnancy may
be due to lack of electrical and metabolic co-ordination
between myometrial smooth-muscle cells. Gap junctions
are specialized protein channels that facilitate the propa-
gation of electrical activity and the exchange of small mol-
ecules between cells. Thus, the appearance of gap
junctions in myometrium is thought to herald the onset
of labour in animals and humans [31-33]. GJA1 (con-
nexin 43) is one of the main structural proteins in myo-
metrial gap junctions; its expression is stimulated by
oestradiol and inhibited by progesterone [34]. Detailed
studies of GJA1 gene regulation indicate that the family of
activator protein-1 transcription factors is critical to deter-
mine the level of GJA1 expression in myometrial cells
[35,36]. Retinoic acid upregulates GJA1 expression in
human endometrial and myometrial cells probably
through nuclear receptors [37,38]. A number of protein
kinases are involved in the functional regulation of GJA1,
including PRKA, PRKC and mitogen-activated protein
kinase 1 (MAPK1). Phosphorylation at Ser-368 seems
important for translocation of GJA1 from the cytosol and
its assembly on the plasma membrane [39]. On the other
hand phosphorylation of GJA1 and other connexins may
also trigger internalization and degradation [40]. In this
regard it is interesting to note that activation of MAPK1 in
pregnant rat myometrium leads to phosphorylation of
GJA1 at Ser-255 and this causes a loss of amplitude and
synchronization of uterine contractions [41]. In mice,
conditional deletion of the GJA1 gene causes a dramatic
delay in parturition [42]. A better understanding of the
pathways that regulate GJA1 expression and phosphoryla-
tion in human myometrium should clarify the role of
these proteins during pregnancy and labour.
Human chorionic gonadotrophin (hCG) has an essential
role in prolonging the life of the corpus luteum to allow
the establishment of pregnancy and its continuation
through the first trimester. There is some evidence that in
addition to its effect on the ovary hCG has a direct effect
on myometrial smooth muscle to promote uterine quies-
cence. Receptors for hCG (LHCGR) have been described
in human pregnant and non-pregnant myometrium;
interestingly the binding of hCG to myometrial tissue
decreases during term and preterm labour [43]. The appli-
cation of hCG to human myometrial strips obtained from
late pregnant women inhibits contractility [44] and this
raises the intriguing possibility that placental gonado-
trophin is an endogenous tocolytic agent. The action of
hCG involves positive coupling to ADCY through
LHCGR-Gαs and inhibition of intracellular Ca2+ fluxes
through a cAMP/PRKA mechanism [45]. It is no clear
what targets are phosphorylated by PRKA upon stimula-BMC Pregnancy and Childbirth 2007, 7(Suppl 1):S2 http://www.biomedcentral.com/1471-2393/7/S1/S2
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tion of the LHCGR but the available evidence suggest that
hCG antagonises proteins involved in oxytocin signalling
[45]. Moreover, activation of LHCGR in human myome-
trial cells leads to loss of gap junction formation and
downregulation of GJA1 protein by a PRKA mediated
effect [46]. Another mechanism by which the LHCGR can
promote uterine quiescence is through inhibition of the
phosphodiesterase PDE5 gene in human myometrial
cells, thus potentiating the effect of cyclic nucleotides
[47].
Recent data suggest that the regulation of the LHCGR gene
in human myometrium involves the binding of specificity
protein (Sp)-like transcription factors to the proximal pro-
moter region of the gene. SP1, SP3 and SP4 proteins are
involved in recruiting histone deacetylases to the pro-
moter, blocking transcriptional activation by preventing
chromatin remodelling [48]. A previous report had sug-
gested that parturition in women and mice is associated
with a loss of co-activators containing histone deacetylase
activity in the uterus [23]. SP proteins are activated by
PRKA [49] providing a feedback mechanism by which
cAMP can regulate the level of LHCGR expression. More-
over there is some evidence that hCG may be involved in
the upregulation of Gαs protein observed in human myo-
metrium in pregnancy [50]; the transcriptional activity of
the Gαs promoter in human myometrial cells is modu-
lated by hCG in a biphasic manner by a mechanism that
appears to involve PRKA activation of SP1 [51].
The management of preterm labour
The most commonly used drugs for the treatment of
threatened preterm labour have been the betamimetics.
Ritodrine and terbutaline were introduced as selective β2-
adrenoceptor (ADRB2) agonists and in 1980 the FDA
approved ritodrine hydrochloride for use in preterm
labour. ADRB2 receptors are positively coupled to Gαs/
ADCY and their effects are mediated by the cAMP path-
way; although the exact mechanism of action is not
known it is likely to involve activation of PRKA and phos-
phorylation of proteins involved in smooth muscle relax-
ation. Betamimetics are effective at delaying delivery in
women in preterm labour for 48 hours, but there is no evi-
dence that this relatively short delay provides any benefit
in terms of perinatal mortality or morbidity [52]. Stimula-
tion of ADRB2 receptors results in desensitization and
downregulation. Short term tocolysis with intravenous
ritodrine may be helpful to transfer women in preterm
labour to a hospital with better neonatal facilities or to
allow time to complete a course of antenatal glucocorti-
coids, but even these advantages are controversial. Long
term tocolysis with oral terbutaline for maintenance ther-
apy after threatened preterm labour shows no benefit
compared to placebo [53]. The use of ADRB2 agonists is
associated with unpleasant and potentially serious cardio-
vascular, metabolic and neuromuscular side effects and
this represents a major drawback to their clinical use. As
reported in this issue, new data show that the predomi-
nant  β-adrenoceptor in late pregnant human myo-
metrium is the β3-adrenoceptor (ADRB3) rather than the
ADRB2 [54]. Stimulation of ADRB3 relaxes pregnant
myometrial strips probably by opening potassium chan-
nels [55]. It will be of interest to explore the development
of specific ADRB3 agonists as potential tocolytic agents.
Oxytocin has a prominent role in promoting strong uter-
ine contractions in the later stages of labour and in the
immediate puerperium, and in facilitating milk ejection
during lactation. The concentration of myometrial OXTR
is very high in late pregnancy, making the uterus very sen-
sitive to oxytocin [56-58] and providing a relatively selec-
tive pharmacological target [59]. In 2000 atosiban
became the first oxytocin antagonist specifically approved
for the management of preterm labour. Atosiban is a com-
petitive inhibitor of the OXTR and blocks OXT-induced
Ca2+ increase in myometrial cells in a reversible manner
[60]. However atosiban has a high affinity for the vaso-
pressin AVPR1A receptor and this may result in unwanted
side effects. Clinical trials with atosiban are encouraging
but inconclusive; most studies have compared its tocolytic
efficacy with that of betamimetics and the results show
that it is at least as efficient and with a much lower fre-
quency of side effects [61,62]. A new generation of OXT
antagonists includes barusiban which is more potent than
atosiban and very selective for OXTR versus AVPR1A
receptors [63]. Other approaches include the develop-
ment of non-peptide orally active OXTR antagonists
[64,65]. The potential of these drugs for the management
of preterm labour should be investigated with appropriate
clinical trials.
Progress in the management of preterm labour has been
hampered by our lack of understanding of the process of
parturition in humans and by the unavailability of drugs
capable of inhibiting uterine contractility efficiently, with-
out causing potentially serious side effects for the mother
or the baby. Conventional tocolytic agents e.g. β2-adreno-
ceptor (ADRB2) agonists, calcium channel antagonists,
prostaglandin synthesis inhibitors), all lack uterine selec-
tivity. The effectiveness of oxytocin antagonists is not
proven. New approaches to develop better drugs for the
management of preterm labour discussed in this issue
include studies on prostaglandin PTGFR receptor antago-
nists, and phosphodiesterase (PDE4) inhibitors. More
research is necessary to identify the physiological trigger
for parturition and to understand why the process may be
activated prematurely in some pregnancies. It is also nec-
essary to investigate the biochemical mechanisms regulat-
ing uterine smooth muscle activity in order to develop
more effective and selective therapy to control uterineBMC Pregnancy and Childbirth 2007, 7(Suppl 1):S2 http://www.biomedcentral.com/1471-2393/7/S1/S2
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contractions when this is indicated. Parturition is a com-
plex physiological event involving integrated functional
responses in several maternal and fetal organs. It is likely
that broad genomic and proteomic approaches will high-
light relevant mechanisms, however I believe it is impor-
tant to focus on improving our understanding of the
regulation and signalling pathways of receptors whose
influence on uterine contractility is well established.
The need to promote research into preterm 
labour
The quality of research into human parturition and pre-
term labour in Europe is high, attested by the continuing
presence of European speakers at the major North Ameri-
can and other international obstetric and perinatal scien-
tific meetings and by the regular appearance of excellent
manuscripts from European laboratories in top peer-
reviewed journals. However this high quality output
reflects rather fragmented research efforts from enthusias-
tic groups that work in relative isolation. There is a need
for concerted research efforts from different European lab-
oratories to make substantial contributions towards solv-
ing the problem of preterm labour. This will require
traditional physiological and biochemical studies as well
as incorporating modern genomic and proteomic
approaches and new imaging techniques, electromyogra-
phy, bioengineering and nanotechnology. Moreover the
development of any new diagnostic methods or uterine-
selective drugs must be validated with appropriately
designed clinical trials. The European Commission con-
tinues to promote high quality research to improve the
health and wellbeing of European citizens and those in
underprivileged countries of the world. A comprehensive
FP7 funding programme has just been launched. The
meetings in Tarragona, and subsequent meetings in Lon-
don and Paris have resulted in the creation of a European
Preterm Labour Group of investigators to cement collabo-
ration and publicise the need to invest research funds into
a better understanding of human parturition and preterm
labour, so that most women can benefit from a successful
pregnancy and a healthy newborn.
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